Laboratory of Biotechnology, Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Lavrentjeva Av. 8, Novosibirsk, 630090, Russia.
Budker Institute of Nuclear Physics, Siberian Branch of the Russian Academy of Sciences, Lavrentjeva Av. 11, Novosibirsk, 630090, Russia.
Cancer Commun (Lond). 2020 Sep;40(9):406-421. doi: 10.1002/cac2.12089. Epub 2020 Aug 17.
The development of new accelerators has given a new impetus to the development of new drugs and treatment technologies using boron neutron capture therapy (BNCT). We analyzed the current status and future directions of BNCT for cancer treatment, as well as the main issues related to its introduction. This review highlights the principles of BNCT and the key milestones in its development: new boron delivery drugs and different types of charged particle accelerators are described; several important aspects of BNCT implementation are discussed. BCNT could be used alone or in combination with chemotherapy and radiotherapy, and it is evaluated in light of the outlined issues. For the speedy implementation of BCNT in medical practice, it is necessary to develop more selective boron delivery agents and to generate an epithermal neutron beam with definite characteristics. Pharmacological companies and research laboratories should have access to accelerators for large-scale screening of new, more specific boron delivery agents.
新型加速器的发展为使用硼中子俘获治疗（BNCT）的新药和治疗技术的发展注入了新的动力。我们分析了 BNCT 用于癌症治疗的现状和未来方向，以及引入过程中的主要问题。本综述强调了 BNCT 的原理及其发展的关键里程碑：描述了新的硼输送药物和不同类型的带电粒子加速器；讨论了 BNCT 实施的几个重要方面。BNCT 可以单独使用或与化疗和放疗联合使用，并根据所概述的问题进行评估。为了在医学实践中迅速实施 BNCT，有必要开发更具选择性的硼输送剂，并产生具有明确特性的超热中子束。制药公司和研究实验室应该能够使用加速器对新型、更具特异性的硼输送剂进行大规模筛选。
